LEADER 04906nam 2201261z- 450 001 9910557286503321 005 20231214133314.0 035 $a(CKB)5400000000041175 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69097 035 $a(EXLCZ)995400000000041175 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRheumatoid Arthritis Therapy Reappraisal$eStrategies, Opportunities and Challenges 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (260 p.) 311 $a3-03943-090-4 311 $a3-03943-091-2 330 $aRheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes of drugs have shown to halt disease progression in clinical studies. In real life, a physician has more options than just adding or switching to a new ts/bDMARD if any kind of DMARDs has failed. They can modify or optimize the therapy with concomitant csDMARDs, and oral or IA-GC can be added to the treatment regimen. The EULAR states that therapeutic adjustment including the "optimization of csDMARDs dose or route of administration or intra-articular injections of GCs" is recommended. Thus, a new therapeutic agent can be embedded in a whole strategy with parallel optimization of the csDMARD and GC treatment. The idea of treating to target (T2T) for the treatment of RA patients has been around since the late 1990s. Many clinical studies (Ticora, BsSt, Camera) have demonstrated the superiority of a T2T approach. When I talk to physicians, I understand that most of them only rarely inject joints with GC. Therefore, I would like to create an issue on the T2T approach in reality including primary data, reviews, and real-life data demonstrating the general opinion and execution of T2T in treating RA. 517 $aRheumatoid Arthritis Therapy Reappraisal 606 $aMedicine$2bicssc 610 $arheumatoid arthritis 610 $asleep 610 $asleep disorders 610 $apain 610 $aosteoporosis 610 $afracture 610 $afracture risk assessment tool 610 $atreat-to-target 610 $acertolizumab pegol 610 $acsDMARDs 610 $aglucocorticoids 610 $aintra-articular injections 610 $aDAS 28 610 $aACR response 610 $aHAQ-DI 610 $aTNF? 610 $agolimumab 610 $aefficacy 610 $atolerability 610 $aimmunogenicity 610 $amethotrexate 610 $aposology 610 $atitration 610 $aoral route 610 $asubcutaneous route 610 $abioavailability 610 $aeffectiveness 610 $aperiodontitis 610 $aperiodontal disease 610 $aanti-citrullinated protein autoantibodies 610 $arheumatoid factor 610 $asmoking 610 $amedication 610 $aPorphyromonas gingivalis 610 $aRheumatoid arthritis 610 $amatrix metalloproteinase 3 610 $ainfliximab 610 $apharmacogenomics 610 $aanti-TNF 610 $apersonalized medicine 610 $abaricitinib 610 $adisease-modifying antirheumatic drugs 610 $apain perception 610 $aoutcomes research 610 $apatient perspective 610 $aRheumatoid Arthritis 610 $atherapy 610 $aDMARD 610 $aMTX 610 $aTumor Necrosis Factor-Alpha Inhibitors 610 $aankylosing spondylitis 610 $abiosimilar 610 $aswitching 610 $asynovial fibroblasts 610 $acytokine 610 $aosteoclast 610 $aherbal medicine 610 $amethylation 610 $anext-generation sequencing 610 $arecovery of function 610 $afatigue 610 $aproductivity 610 $atofacitinib 610 $aoral 610 $aTh1.17 610 $aIL-17A 610 $aIFN-?, CD73 610 $aadenosine 610 $apsoriatic arthritis 610 $aregulation 610 $apseudoerosions 610 $ahand 610 $afoot 610 $aultrasonography 610 $aradiography 610 $acomputed tomography 610 $amagnetic resonance imaging 615 7$aMedicine 700 $aMu?ller$b Ru?diger$4edt$01310955 702 $aMu?ller$b Ru?diger$4oth 906 $aBOOK 912 $a9910557286503321 996 $aRheumatoid Arthritis Therapy Reappraisal$93029949 997 $aUNINA